RecruitingPhase 2ACTRN12607000633482

Global Prevention of Asthma in Children Study

A Phase II Multicenter, Controlled, Double-Blind Study Using Immunoprophylaxis in the Primary Prevention of Allergic Disease


Sponsor

National Institute of Allergy and Infectious Diseases

Enrollment

200 participants

Start Date

Jun 1, 2006

Study Type

Interventional

Conditions


Eligibility

Sex: Both males and femalesMin Age: 12 MonthssMax Age: 30 Monthss

Inclusion Criteria5

  • Diagnosed with eczema (atopic dermatitis)
  • Family history of eczema, allergic rhinitis, or asthma
  • Allergy to one or more of the following: egg white, cow’s milk, peanut, or soybean
  • Weigh at least 8.0 kg
  • Parent or guardian willing to provide informed consent

Exclusion Criteria9

  • Allergy to house dust mite, cat, or timothy grass
  • Born prematurely (before 36th week's gestation) 3. Previous diagnosis of asthma OR have had 3 or more distinct episodes of wheeze during the first year of life
  • Chronic pulmonary disease
  • Chronic disease requiring therapy
  • Past or current treatment with systemic immunomodulator medication
  • Past or current treatment with allergen-specific immunotherapy
  • Received 10 or more days of systemic steroids in the 3 months prior to study entry
  • Orofacial abnormalities that are likely to interfere with the volunteer's ability to take study treatment
  • Participated in another clinical study within the 3 months prior to study entry

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

House Dust Mites - 7.5 mcg/0.2ml (Dermatophagoides pteronyssinus & Dermatophagoides farinae); Cat (11.3 mcg/0.2ml) and Timothy Grass (15.0 mcg/0.2ml) or matching placebo orally once daily for 12 month

House Dust Mites - 7.5 mcg/0.2ml (Dermatophagoides pteronyssinus & Dermatophagoides farinae); Cat (11.3 mcg/0.2ml) and Timothy Grass (15.0 mcg/0.2ml) or matching placebo orally once daily for 12 months


Locations(3)

New York, United States of America

Berlin, Germany

Stockholm, Sweden

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12607000633482


Related Trials